Diagnostic Radioisotopes Market Report 2026

Diagnostic Radioisotopes Market Overview

• Diagnostic Radioisotopes market size has reached to $6.08 billion in 2025 • Expected to grow to $9.26 billion in 2030 at a compound annual growth rate (CAGR) of 8.5% • Growth Driver: Rising Global Cancer Burden Driving Demand For Market Due To Ageing Populations And Increased Risk Factor Exposure • Market Trend: Innovative PET Tracers Enhance Precision In Brain Cancer Imaging • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Diagnostic Radioisotopes Market?

Diagnostic radioisotopes refer to radioactive isotopes used in the field of nuclear medicine to diagnose and monitor various medical conditions. They utilize their radioactive decay properties to emit radiation, which is detected by specialized imaging equipment, allowing healthcare professionals to obtain detailed images of internal body structures and assess their function. The main radioisotopes of diagnostic radioisotopes are technetium-99m, thallium-201, gallium-67, iodine-123, fluorodeoxyglucose (FDG), rubidium-82, and others. Technetium-99m radioisotopes are utilized extensively in medical imaging procedures due to their favorable nuclear properties and widespread availability. The imaging modalities encompass single photon emission computed tomography (SPECT), positron emission tomography (PET), and beta emitters, utilized for various applications including oncology, cardiology, and others.

What Is The Diagnostic Radioisotopes Market Growth Forecast?

The diagnostic radioisotopes market size is expected to see strong growth in the next few years. It will grow to $9.26 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increase in oncology imaging demand, expansion of cardiac nuclear diagnostics, new radioisotope development, regional isotope production investments, aging population diagnostics needs. Major trends in the forecast period include increasing use of pet and spect imaging, rising demand for oncology radioisotopes, expansion of nuclear medicine diagnostics, growing adoption of short-half-life isotopes, improved radiopharmaceutical supply chains.

Global Diagnostic Radioisotopes Market Segmentation

1) By Radioisotope: Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FluoroDeoxyGlucose (FDG), Rubidium-82, Other Radioisotopes 2) By Imaging Modality: Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), Beta Emitters 3) By Application: Oncology, Cardiology, Other Applications 4) By End User: Hospitals, Specialty Clinics, Diagnostic Centers, Academic And Research Institutes, Other End Users Subsegments: 1) By Technetium-99m: Diagnostic Imaging, Cardiac Imaging, Oncology Imaging, Bone Scans, Renal Scans 2) By Thallium-201: Cardiac Imaging, Myocardial Perfusion Imaging, Stress Tests 3) By Gallium-67: Oncology Imaging (Lymphoma, Tumors), Inflammatory Disease Imaging, Infection Imaging 4) By Iodine-123: Thyroid Imaging, Neurological Imaging (Parkinson's Disease), Cardiac Imaging 5) By FluoroDeoxyGlucose (FDG): Positron Emission Tomography (PET) Imaging, Cancer Diagnosis And Staging, Neurological Imaging, Cardiac Imaging 6) By Rubidium-82: Cardiac PET Imaging, Myocardial Perfusion Imaging, Coronary Artery Disease Diagnosis 7) By Other Radioisotopes: Strontium-89 (Bone Pain Palliation), Iodine-131 (Thyroid Cancer Treatment), Samarium-153 (Bone Pain Palliation), Yttrium-90 (Cancer Treatment)

What Is The Driver Of The Diagnostic Radioisotopes Market?

The rising burden of cancer is expected to propel the growth of the diagnostic radioisotopes market going forward. Cancer refers to a disease characterized by the uncontrolled division of abnormal cells, which can invade surrounding tissues and spread throughout the body. The rising global cancer burden is driven by demographic shifts such as population aging and growth, as well as greater exposure to risk factors including tobacco use, obesity, and environmental pollutants. Diagnostic radioisotopes support healthcare by enabling precise imaging, early detection, and effective monitoring of cancer progression or treatment response. For instance, in October 2025, according to the National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, an average of 972 per day, which is 8,605 more than in 2022. Therefore, the rising global cancer burden is driving the growth of the diagnostic radioisotopes industry.

Key Players In The Global Diagnostic Radioisotopes Market

Major companies operating in the diagnostic radioisotopes market are Cardinal Health Inc., Lantheus Holdings, Curium Pharma, Clarity Pharmaceuticals, Bracco Diagnostic Inc., Nordion Inc., Eckert & Ziegler AG, NorthStar Medical Radioisotopes LLC, NTP Radioisotopes SOC Ltd, Isotopia Molecular Imaging Ltd, Cyclopharm Limited, Trasis NV, ARTMS Inc, Radiomedix Inc, Coqu RadioPharmaceuticals Corp, ANSTO, IRE Institute for Radioelements, NRG, China National Nuclear Corporation, Polatom, Niowave Inc, JSC Isotope, Center of Molecular Research, Oak Ridge National Laboratory, SHINE Technologies

Global Diagnostic Radioisotopes Market Trends and Insights

Major companies operating in the diagnostic radioisotopes market are focusing on incorporating trends such as next-generation positron emission tomography (PET) imaging radiotracers to enhance diagnostic accuracy, early-stage detection, and clinical decision-making. Next-generation PET radiotracers are advanced radioactive imaging agents engineered to bind to specific molecular or metabolic targets, enabling high-resolution visualization of tumors and metastatic lesions. For instance, in July 2024, Radiopharm Theranostics Limited, an Australia-based radiopharmaceutical and theranostics development company, received US Food and Drug Administration (FDA) Investigational New Drug (IND) approval for F18-Pivalate (RAD 101), a Fluorine-18 (F-18) labeled PET imaging agent designed for the detection of suspected recurrent brain metastases by targeting Fatty Acid Synthase (FASN) overexpressed in solid tumors. The radiotracer features high tumor-to-background contrast, favorable imaging kinetics, and compatibility with existing PET systems. F18-Pivalate (RAD 101) improves diagnostic precision, supports more accurate identification of metastatic disease, and strengthens clinical decision-making in oncology care.

What Are Latest Mergers And Acquisitions In The Diagnostic Radioisotopes Market?

In April 2024, Telix Pharmaceuticals Limited, an Australia-based biotechnology company, acquired ARTMS for an undisclosed amount. Through acquisition of ARTMS, Telix Pharmaceuticals aims to bolster its supply chain and manufacturing, leveraging its cyclotron-based isotope production expertise to enhance market position and meet rising demand for diagnostic and therapeutic isotopes. ARTMS is a Canada-based provider of radioisotope technology and specializes in diagnostic radioisotopes.

Regional Outlook

North America was the largest region in the diagnostic radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Diagnostic Radioisotopes Market?

The diagnostic radioisotopes market consists of revenues earned by entities by providing services such as radiopharmacy services, imaging services, radioisotope production and supply, diagnostic procedures, and theranostics. The market value includes the value of related goods sold by the service provider or included within the service offering. The diagnostic radioisotopes market also includes sales of products including Indium-111, Xenon-133, Molybdenum-99, and Phosphorus-32. Values in this market are 'factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Diagnostic Radioisotopes Market Report 2026?

The diagnostic radioisotopes market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic radioisotopes industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.